Category: 89396-94-1

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalubuminuric patients with type II diabetes, the main research direction is ACE inhibitor amlodipine hypertension diabetes microalbuminuria.Synthetic Route of C20H28ClN3O6.

It has been demonstrated that antihypertensive treatment of hypertensive diabetic patients is quite effective in preventing and microvascular complications and improving prognosis. Nevertheless, the target blood pressure level of antihypertensive treatment in hypertensive diabetic patients with microalbuminuria (i.e., with early diabetic nephropathy) remains to be established. In this study, we evaluated the effect of intensive blood pressure control (diastolic blood pressure <80 mmHg) on urinary albumin excretion in hypertensive, type II diabetic patients with microalbuminuria. We examined the effects of a combination therapy using an angiotensin-converting enzyme (ACE) inhibitor plus a long-acting calcium channel blocker (amlodipine), and compared them with the effect of an ACE inhibitor alone. Thirty hypertensive, type II diabetic patients with microalbuminuria were treated with either an ACE inhibitor alone (group I, n = 17) or an ACE inhibitor plus amlodipine (group II, n = 13) for 32 wk. With treatment, blood pressures in both groups were significantly reduced, and diastolic blood pressure was lowered to a much greater extent in group II (76±2 mmHg) than in group I (83±2 mmHg, p<0.05). Although the urinary albumin excretion rate was decreased in both groups, the decrease attained statistical significance only in group II (from 141±25 mg/day to 69±18 mg/day, p<0.05); the extent of reduction in microalbuminuria during antihypertensive treatment was significantly greater in group II (50±10%) than in group I (14±13%, p<0.05). In conclusion, this study showed that in hypertensive microalbuminuric type II diabetic patients, the combination of an ACE inhibitor plus amlodipine resulted in a more pronounced decreased in blood pressure (diastolic blood pressure <80 mmHg) and a greater reduction in urinary albumin excretion than did use of an ACE inhibitor alone. This combination strategy should thus be a more effective tool for obtaining optimal blood pressure control in patients with diabetic nephropathy. There is still a lot of research devoted to this compound(SMILES：O=C([C@H](CN1C)N(C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)C1=O)O.[H]Cl)Synthetic Route of C20H28ClN3O6, and with the development of science, more effects of this compound(89396-94-1) can be discovered.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Clinicopathological factors that affect the therapeutic benefits of inhibitors of the renin angiotensin system in patients with IgA nephropathy, published in 2004-11-25, which mentions a compound: 89396-94-1, Name is (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, Molecular C20H28ClN3O6, HPLC of Formula: 89396-94-1.

Recent studies have shown that inhibitors of the renin-angiotensin system (I-RAS) such as angiotensin converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) are effective for IgA nephropathy (IgAN). However, the precise mechanism of the effects remains unknown. The present study was conducted to elucidate the pathol. factors affecting the therapeutic benefits of I-RAS in IgAN. Twenty-six IgAN patients were studied retrospectively. The patients were divided into two groups according to the grade of reduction of urinary protein excretion: the responder group (n = 12) and the non-responder group (n = 14). The modality of treatment was determined by the clin. and histol. findings of each patient. No significant difference before treatment was observed between the responder and non-responder groups. In the evaluation of the outcome after treatment, the amounts of urinary protein excretion one year after treatment and at the final observation significantly decreased in the responder group but remained unchanged in the non-responder group. However, the levels of serum-creatinine, urinary red blood cell sediment, and mean blood pressure were not significantly different between both groups. Histol., the rate of glomerular obsolescence, interstitial inflammatory cell infiltration and interstitial fibrosis tended to be higher in the non-responder group than in the responder group, and the rate of crescent formation tended to be higher in the responder group than in the non-responder group, but did not reach statistical significance. The grades of mesangial cell proliferation and mesangial matrix increase were not significantly different between both groups. The grade of arterio- and arteriolosclerosis was significantly higher in the non-responder group than in the responder group (0.92 ± 0.52 vs. 1.91 ± 1.08, p = 0.043, 1.08 ± 0.79 vs. 1.78 ± 0.97, p = 0.033). These findings suggest that arterio- and arteriolo-sclerosis could be a predictor for the effectiveness of I-RAS in IgAN patients.

There is still a lot of research devoted to this compound(SMILES：O=C([C@H](CN1C)N(C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)C1=O)O.[H]Cl)HPLC of Formula: 89396-94-1, and with the development of science, more effects of this compound(89396-94-1) can be discovered.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride( cas:89396-94-1 ) is researched.COA of Formula: C20H28ClN3O6.Shimoishi, Kazuki; Anraku, Makoto; Uto, Ayako; Iohara, Daisuke; Hirayama, Fumitoshi; Kadowaki, Daisuke; Zingami, Sachiko; Maruyama, Toru; Otagiri, Masaki published the article 《A comparison of the phosphorus content in prescription medications for hemodialysis patients in Japan》 about this compound( cas:89396-94-1 ) in Yakugaku Zasshi. Keywords: phosphorus medication hemodialysis Japan; branded; generic; hemodialysis; phosphorus; prescribed medication. Let’s learn more about this compound (cas:89396-94-1).

A high dietary intake of phosphorus is considered to be a significant health threat for hemodialysis (HD) patients. Prescription medications, which might be a major source of phosphorus, is largely unrecognized in Japan. However, the amount of phosphorus indicated on the package label, is not quantified. In this study, the phosphorus content of 22 of the most widely prescribed medications that are used in conjunction with HD therapy were examined and differences between branded and generic prescription medications were compared. All samples were selected from medications that are typically prescribed for HD patients. The samples were ground prior to anal. Phosphorus was measured using the Wako L-Type Phosphate method. All instruments used in the study were calibrated according to the manufacturers’ specifications. Amlodipine (15 mg/tablet) and paroxetine (30.0 mg/tablet) were found to contain higher contents of phosphorus than the medications tested. Differences in phosphorus content between branded and generic drugs was also determined The phosphorus content of all generic paroxetine preparations was significantly lower than the values for identical branded medications. On the other hand, the phosphorus content of several generic amlodipine preparations were significantly different from those of similar, branded preparations Specific information regarding the phosphorus content of prescribed medications used by HD patient needs to be made available to the dialysis community.

If you want to learn more about this compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride)COA of Formula: C20H28ClN3O6, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(89396-94-1).

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

COA of Formula: C20H28ClN3O6. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Kinetics and mechanism of solid state imidapril hydrochloride degradation and its degradation impurities identification. Author is Regulska, Katarzyna; Stanisz, Beata.

A detailed stability testing of solid state imidapril hydrochloride (IMD) was performed and its degradation products were identified. The anal. was conducted according to ICH guidelines Q1A(R2). Pure IMD samples were exposed to stress conditions of elevated temperature and relative humidity (T = 363 K, RH = 76.4%) to accelerate degradation The regular loss of IMD content with time, and the formation of 2 degradation impurities were observed The appropriate reaction rate constants k (for IMD degradation and for the formation of product I and II) were calculated using Prout-Tompkins equation. The obtained degradation products were separated and identified by LC-MS technique. Based on the obtained m/z values, the masses and the structures of the formed degradation impurities were established. Also IMD degradation scheme was constructed. It was demonstrated that under the applied anal. conditions, IMD degradation follows an autocatalytic reaction model with the rate constant k = 4.764 × 10-6 s-1 and with the parallel formation of 2 degradation products: imidaprilat and the diketopiperazine derivative The obtained exptl. results are in agreement with IMD degradation pathways proposed theor.

If you want to learn more about this compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride)COA of Formula: C20H28ClN3O6, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(89396-94-1).

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 89396-94-1, is researched, SMILESS is O=C([C@H](CN1C)N(C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)C1=O)O.[H]Cl, Molecular C20H28ClN3O6Journal, Article, Journal of Pharmaceutical and Biomedical Analysis called Application of quantitative NMR for purity determination of standard ACE inhibitors, Author is Shen, Shi; Yang, Xing; Shi, Yaqin, the main research direction is NMR purity thiol ene click reaction; ACE inhibitors; Captopril; Diastereoisomers; Thiol-ene click reaction; qNMR.Application In Synthesis of (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride.

This study investigated the accuracy of the quant. NMR method for purity determination of ACE inhibitors reference standards and the discovery of two pairs of new diastereoisomers. Six types of ACE inhibitors, imidapril hydrochloride, benazepril hydrochloride, lisinopril, enalapril maleate, quinapril hydrochloride, and captopril were quantificated and validated for the qNMR method by discussing factors that affect parameters of the qNMR experiment, internal standards, integration, pH-effect, and uncertainty. The results were compared with data obtained by the mass balance method. The study found that maleic acid influenced the quantification of captopril in deuteroxide because of a chem. reaction. The mixtures of the reaction products were isolated by HPLC and structurally elucidated by NMR as two pairs of new diastereoisomers, 1-[(2S,4R)-thio-2-methylpropionyl-5-d-ethanedicarboxylicacid]-L-proline and 1-[(2S,4S)-thio-2-methylpropionyl-5-d-ethanedicarboxylicacid]-L-proline. The results showed that the accuracy and precision of quant. 1H NMR spectroscopy satisfied the requirements for quant. anal. of chem. reference standards and provided a simple, rapid, and reliable method for purity determination of ACE inhibitors systematically.

If you want to learn more about this compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride)Application In Synthesis of (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(89396-94-1).

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Watanabe, Kiyoshi; Mito, Seiji; Asano, Yuzo; Hori, Masaki researched the compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride( cas:89396-94-1 ).Product Details of 89396-94-1.They published the article 《Photosensitivity studies of imidapril hydrochloride in guinea pigs》 about this compound( cas:89396-94-1 ) in Oyo Yakuri. Keywords: photosensitivity imidapril hydrochloride UV. We’ll tell you more about this compound (cas:89396-94-1).

Imidapril hydrochloride (imidapril) was examined for its phototoxicity and photosensitization potential in guinea pigs. In a first study, guinea pigs were treated orally with a single dose of 0.1, 1 or 10 mg/kg of imidapril, and then they were irradiated with long-wave UV light (UVA). No phototoxic reaction was observed at any dose of imidapril. In a second study, guinea pigs were sensitized by oral administration of 0.1, 1 or 10 mg/kg or imidapril and irradiated with UVA. No photosensitization reaction was observed at any sensitizing dose of imidapril. Therefore, it is concluded that imidapril has neither phototoxicity nor photosensitization potential in guinea pigs.

If you want to learn more about this compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride)Product Details of 89396-94-1, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(89396-94-1).

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called RP-HPLC method development and validation for the simultaneous estimation of imidapril HCl and amlodipine besylate in bulk and tablet, published in 2013-02-28, which mentions a compound: 89396-94-1, mainly applied to imidapril hydrochloride amlodipine besylate determination reversed phase HPLC, Recommanded Product: 89396-94-1.

A simple reverse phase liquid chromatog. method was developed and subsequently validated for simultaneous determination of imidapril HCl and amlodipine besylate in combination. The separation was carried out using a mobile phase consisting of 0.01M potassium dihydrogen phosphate buffer (adjusted with 0.1% phosphoric acid to pH 3.0), acetonitrile and methanol in the ratio of 50: 35: 15. The column used was Lichrospher C18, 5μm, 25 cm × 4.6 mm maintained at 40°C with flow rate of 1 mL / min using PDA detection at 210 and 237 nm for imidapril HCl and amlodipine besylate resp. The described method was linear over a concentration range of 10-100 μg/mL and 14-140 μg/mL for the assay of imidapril HCl and amlodipine besylate resp. The retention times of imidapril HCl and amlodipine besylate were found to be 4.3 and 6.7 min resp. Results of anal. were validated statistically and by recovery studies. The limit of detection (LOD) and limit of quantification (LOQ) for imidapril HCl and amlodipine besylate were found to be 0.13 and 0.28 μg/mL and 0.24 and 1.47 μg/mL resp. The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of amlodipine besylate and imidapril HCl bulk drug and in its pharmaceutical dosage form.

Here is a brief introduction to this compound(89396-94-1)Recommanded Product: 89396-94-1, if you want to know about other compounds related to this compound(89396-94-1), you can read my other articles.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”